Amplius Wealth Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History
Bought
Maintained
Sold
Other funds holding ARKG
MCMC
Amplius Wealth Advisors's ARKG Position: Q1 2022 in Review
Amplius Wealth Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2022, closing a stake of 356 shares — an estimated $21K sold.
Amplius Wealth Advisors first reported a position in ARKG in Q4 2021 and held it in 1 quarter. The position peaked at $21K in Q4 2021. 387 funds tracked by Wall St. Rank hold ARKG as of Q1 2022.
- Amplius Wealth Advisors reported no remaining ARK Genomic Revolution ETF position as of Q1 2022 after selling out during the quarter.
- Amplius Wealth Advisors sold 356 ARK Genomic Revolution ETF shares in Q1 2022, an estimated $21K.
- Amplius Wealth Advisors first reported a position in ARK Genomic Revolution ETF in Q4 2021 and held it in 1 quarter.
- Amplius Wealth Advisors's ARK Genomic Revolution ETF position peaked at $21K in Q4 2021.
- 387 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2022.
Based on Amplius Wealth Advisors's 13F filing for Q1 2022, filed 9 May 2022.